PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.124.268639 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Cristian Udovicich und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Metastasis-directed therapy (MDT) in oligometastatic renal cell carcinoma (RCC) is typically based on conventional imaging. Prostate-specific membrane antigen (PSMA) PET/CT has shown superiority over conventional imaging. Our objective was to perform a proof-of-concept study to evaluate the efficacy of PSMA-guided MDT in oligometastatic RCC.
Methods
A PSMA PET/CT database was queried for oligometastatic RCC patients undergoing MDT from 2014 to 2020. The primary endpoint was progression-free survival. Secondary endpoints included freedom from local progression, freedom from change in systemic therapy strategy, and overall survival.
Results
A search of 3,095 PSMA PET/CT scans identified 83 RCC patients and 34 receiving MDT to 60 sites. The median follow-up was 4.1 y. Six patients (18%) had synchronous metastatic disease. The median number of metastases was 1 (interquartile range, 1–2). Common sites included bone (19, 32%) and lung (19, 32%). Radiation therapy was delivered to 56 metastases (93%), including stereotactic ablative body and conventional radiotherapy (38 and 18 metastases, respectively), and 4 (7%) underwent surgery. One-, 3-, and 5-y freedom from local progression was 94% (95% CI, 85%–98%), 85% (95% CI, 69%–94%), and 85% (95% CI, 69%–94%), respectively. One-, 3-, and 5-y overall survival was 88% (95% CI, 71%–95%), 71% (95% CI, 52%–84%), and 64% (95% CI, 45%–79%), respectively. One-, 3-, and 5-y progression-free survival was 47% (95% CI, 30%–63%), 26% (95% CI, 13%–42%), and 8% (95% CI, 2%–22%), respectively. One-, 3-, and 5-y freedom from change in systemic therapy strategy was 76% (95% CI, 57%–87%), 65% (95% CI, 45%–79%), and 43% (95% CI, 19%–65%), respectively.
Conclusion
In this proof-of-concept study, PSMA-guided MDT provided durable oncologic outcomes for oligometastatic RCC, even at 5 y. To our knowledge, this study had the first cohort uniformly undergoing PSMA-guided MDT and one of the longest follow-ups of MDT for oligometastatic RCC. With increasing availability, PSMA PET/CT can be rapidly instituted to select patients for MDT and improve outcomes for patients with oligometastatic RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
- Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Zitieren
APA
Udovicich, C., Bressel, M., Manji, J., Ali, M., Au, L., Azad, A. A., Buteau, J. P., Chander, S., Chang, D., Eapen, R., Lawrentschuk, N., Levy, S. M., Moon, D., Murphy, D. G., Perera, M., Shaw, M., Spain, L., Tran, B., Hofman, M. S., & Siva, S. (2025). PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268639
Vancouver
Udovicich C, Bressel M, Manji J, Ali M, Au L, Azad AA, et al. PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268639
BibTeX
@article{Udovicich2025,
author = {Udovicich, Cristian and Bressel, Mathias and Manji, Jamil and Ali, Muhammad and Au, Lewis and Azad, Arun A and Buteau, James P and Chander, Sarat and Chang, David and Eapen, Renu and Lawrentschuk, Nathan and Levy, Sidney M and Moon, Daniel and Murphy, Declan G and Perera, Marlon and Shaw, Mark and Spain, Lavinia and Tran, Ben and Hofman, Michael S and Siva, Shankar},
title = {PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL Study},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.124.268639}
}
EUVIMED